Sonoma Pharmaceuticals, Inc. (SNOA)
$1.26-$0.02 (-1.56%) Latest session
Amy Moss Trombly - Officer
John McLaughlin - Director
Poggetto John Dal - OfficerAmy Moss Trombly - OfficerSonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 6 | 57,500 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
12 Form 4 filings on record, the earliest from Jan 2, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Philippe Weigerstorfer - Director | Grant or award | Stock option (right to buy) | 10,000 | - | - | |
| Amy Moss Trombly - Officer | Grant or award | Restricted Stock Units | 10,000 | $0.00 | - | |
| John McLaughlin - Director | Grant or award | Stock option (right to buy) | 10,000 | - | - | |
| Vanessa Jacoby - Director | Grant or award | Stock option (right to buy) | 10,000 | - | - | |
| Jerome J. Dvonch - Officer | Grant or award | Restricted Stock Units | 10,000 | $0.00 | - | |
| Poggetto John Dal - Officer | Grant or award | Restricted Stock Units | 7,500 | $0.00 | - | |
| Philippe Weigerstorfer - Director | Grant or award | Stock option (right to buy) | 10,000 | - | - | |
| Amy Moss Trombly - Officer | Grant or award | Restricted Stock Units | 10,000 | $0.00 | - | |
| John McLaughlin - Director | Grant or award | Stock option (right to buy) | 10,000 | - | - | |
| Jerome J. Dvonch - Officer | Grant or award | Restricted Stock Units | 5,000 | $0.00 | - | |
| Poggetto John Dal - Officer | Grant or award | Restricted Stock Units | 5,000 | $0.00 | - | |
| Jay E. Birnbaum - Director | Grant or award | Stock option (right to buy) | 10,000 | - | - |
Sonoma Pharmaceuticals, Inc. (SNOA) had 6 insider filings in the last 90 days, with the most recent on 2026-07-10. The full record for SNOA runs to 12 Form 4 filings, the earliest from 2026-01-02. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of SNOA were filed in the last 90 days.
No insider sales of SNOA were filed in the last 90 days.
This page tracks SNOA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add SNOA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
